BIO-TECHNE Corp
13.63xPrice / tangible book
Market cap
$11.30B
Tangible equity (USD)
$829.40M
Price / tangible book
13.63x
Price / book
5.36x
Net income / ending equity
8.6%
Net income / ending assets
7.0%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $11.30B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: TECH stock price at premium vs C $72.08 current versus $22.98 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at C's multiple
Implied fair value · at TECH's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Multiple premium
Multiple premium
Profitability edge
Asset efficiency edge
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / tangible book
Market cap
$11.30B
Tangible equity (USD)
$829.40M
Price / tangible book
13.63x
Price / book
5.36x
Net income / ending equity
8.6%
Net income / ending assets
7.0%
Efficiency ratio
—
Price / tangible book
Market cap
$242.28B
Tangible equity (USD)
$188.91B
Price / tangible book
1.28x
Price / book
1.14x
Net income / ending equity
6.7%
Net income / ending assets
0.5%
Efficiency ratio
64.7%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIO-TECHNE Corp · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Citigroup Inc · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
TECH vs TMO
DANAHER CORP /DE/
TECH vs DHR
AGILENT TECHNOLOGIES, INC.
TECH vs A
WATERS CORP /DE/
TECH vs WAT
ILLUMINA, INC.
TECH vs ILMN
BRUKER CORP
TECH vs BRKR
JPMorgan Chase & Co.
TECH vs JPM
Bank of America Corporation
TECH vs BAC
Wells Fargo & Company
TECH vs WFC
The Goldman Sachs Group, Inc.
TECH vs GS
Morgan Stanley
TECH vs MS
CAPITAL ONE FINANCIAL CORP
TECH vs COF
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.